Understanding the Market | JENSCARE-B rises over 6% as its subsidiary Ken-Valve successfully completes the first batch of commercial implants recently
JENSCARE-B's stock price rose over 6% again, up 4.45% as of the time of writing, priced at HKD 8.92, with a transaction volume of HKD 3.7648 million. The company's core product, Ken-Valve, has successfully completed its first batch of commercial implants, marking the start of its commercialization in China. This product has garnered expert attention at the West China Minimally Invasive Cardiovascular Conference. In the future, the company will expand its sales network, advance the global commercialization process, and optimize production costs to achieve revenue targets
According to Zhitong Finance APP, JENSCARE-B (09877) has risen over 6% again, and as of the time of publication, it is up 4.45%, priced at HKD 8.92, with a transaction volume of HKD 3.7648 million.
In terms of news, JENSCARE recently announced that one of its core products, the transcatheter aortic valve replacement (TAVR) product Ken-Valve, has successfully completed its first batch of commercial implants in a series of hospitals across key provinces and cities in the country. The largest valve size used is 33mm, and the shortest device operation time is about 5 minutes. At the recently concluded 2025 West China Minimally Invasive Cardiovascular Conference and the 8th Western Valve Forum, Ken-Valve successfully completed multiple live surgeries, successfully performing aortic valve interventions for several patients with complex anatomical structures, including those with oversized annuli and horizontal hearts. The design features, operational advantages, and applicable scope of Ken-Valve received enthusiastic discussion and attention from attending experts.
The announcement stated that the successful implementation of the first batch of commercial implants marks the successful launch and smooth advancement of Ken-Valve's commercialization in China, representing an important milestone for the product and the company's commercialization process. The company will continue to take various measures to seize market opportunities, expand its sales network, and continuously promote the global commercialization process of its core products, including Ken-Valve and LuX-Valve series products; at the same time, the company will continue to optimize production costs and operational efficiency to achieve its revenue goals as soon as feasible
